Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Impact of Type III Secretion Effectors and of Phenoxyacetamide Inhibitors of Type III Secretion on Abscess Formation in a Mouse Model of Pseudomonas aeruginosa Infection.

Berube BJ, Murphy KR, Torhan MC, Bowlin NO, Williams JD, Bowlin TL, Moir DT, Hauser AR.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01202-17. doi: 10.1128/AAC.01202-17. Print 2017 Nov.

2.

A Sensitive in Vitro High-Throughput Screen To Identify Pan-filoviral Replication Inhibitors Targeting the VP35-NP Interface.

Liu G, Nash PJ, Johnson B, Pietzsch C, Ilagan MX, Bukreyev A, Basler CF, Bowlin TL, Moir DT, Leung DW, Amarasinghe GK.

ACS Infect Dis. 2017 Mar 10;3(3):190-198. doi: 10.1021/acsinfecdis.6b00209. Epub 2017 Feb 9.

3.

DNA Targeting as a Likely Mechanism Underlying the Antibacterial Activity of Synthetic Bis-Indole Antibiotics.

Opperman TJ, Kwasny SM, Li JB, Lewis MA, Aiello D, Williams JD, Peet NP, Moir DT, Bowlin TL, Long EC.

Antimicrob Agents Chemother. 2016 Nov 21;60(12):7067-7076. Print 2016 Dec.

4.

Beyond Antibiotics: New Therapeutic Approaches for Bacterial Infections.

Hauser AR, Mecsas J, Moir DT.

Clin Infect Dis. 2016 Jul 1;63(1):89-95. doi: 10.1093/cid/ciw200. Epub 2016 Mar 29.

5.

Novel Small Molecule Entry Inhibitors of Ebola Virus.

Basu A, Mills DM, Mitchell D, Ndungo E, Williams JD, Herbert AS, Dye JM, Moir DT, Chandran K, Patterson JL, Rong L, Bowlin TL.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S425-34. doi: 10.1093/infdis/jiv223. Epub 2015 Jul 22.

6.

Discovery of bacterial fatty acid synthase type II inhibitors using a novel cellular bioluminescent reporter assay.

Wallace J, Bowlin NO, Mills DM, Saenkham P, Kwasny SM, Opperman TJ, Williams JD, Rock CO, Bowlin TL, Moir DT.

Antimicrob Agents Chemother. 2015 Sep;59(9):5775-87. doi: 10.1128/AAC.00686-15. Epub 2015 Jul 13.

7.

Synthesis and structure-activity relationships of novel phenoxyacetamide inhibitors of the Pseudomonas aeruginosa type III secretion system (T3SS).

Williams JD, Torhan MC, Neelagiri VR, Brown C, Bowlin NO, Di M, McCarthy CT, Aiello D, Peet NP, Bowlin TL, Moir DT.

Bioorg Med Chem. 2015 Mar 1;23(5):1027-43. doi: 10.1016/j.bmc.2015.01.011. Epub 2015 Jan 13.

8.

Mutations in the Pseudomonas aeruginosa needle protein gene pscF confer resistance to phenoxyacetamide inhibitors of the type III secretion system.

Bowlin NO, Williams JD, Knoten CA, Torhan MC, Tashjian TF, Li B, Aiello D, Mecsas J, Hauser AR, Peet NP, Bowlin TL, Moir DT.

Antimicrob Agents Chemother. 2014;58(4):2211-20. doi: 10.1128/AAC.02795-13. Epub 2014 Jan 27.

9.

Potent and broad-spectrum antibacterial activity of indole-based bisamidine antibiotics: synthesis and SAR of novel analogs of MBX 1066 and MBX 1090.

Williams JD, Nguyen ST, Gu S, Ding X, Butler MM, Tashjian TF, Opperman TJ, Panchal RG, Bavari S, Peet NP, Moir DT, Bowlin TL.

Bioorg Med Chem. 2013 Dec 15;21(24):7790-806. doi: 10.1016/j.bmc.2013.10.014. Epub 2013 Oct 25.

10.

New small molecule entry inhibitors targeting hemagglutinin-mediated influenza a virus fusion.

Basu A, Antanasijevic A, Wang M, Li B, Mills DM, Ames JA, Nash PJ, Williams JD, Peet NP, Moir DT, Prichard MN, Keith KA, Barnard DL, Caffrey M, Rong L, Bowlin TL.

J Virol. 2014 Feb;88(3):1447-60. doi: 10.1128/JVI.01225-13. Epub 2013 Nov 6.

11.

Characterization of the Burkholderia thailandensis SOS response by using whole-transcriptome shotgun sequencing.

Ulrich RL, Deshazer D, Kenny TA, Ulrich MP, Moravusova A, Opperman T, Bavari S, Bowlin TL, Moir DT, Panchal RG.

Appl Environ Microbiol. 2013 Oct;79(19):5830-43. doi: 10.1128/AEM.00538-13. Epub 2013 Jul 19.

12.

Optimization of a novel potent and selective bacterial DNA helicase inhibitor scaffold from a high throughput screening hit.

Li B, Pai R, Aiello D, Di M, Barnes MH, Peet NP, Bowlin TL, Moir DT.

Bioorg Med Chem Lett. 2013 Jun 15;23(12):3481-6. doi: 10.1016/j.bmcl.2013.04.055. Epub 2013 Apr 30.

13.

Coumarin-based inhibitors of Bacillus anthracis and Staphylococcus aureus replicative DNA helicase: chemical optimization, biological evaluation, and antibacterial activities.

Li B, Pai R, Di M, Aiello D, Barnes MH, Butler MM, Tashjian TF, Peet NP, Bowlin TL, Moir DT.

J Med Chem. 2012 Dec 27;55(24):10896-908. doi: 10.1021/jm300922h. Epub 2012 Dec 11.

14.

Bis-imidazolinylindoles are active against methicillin-resistant Staphylococcus aureus and multidrug-resistant Mycobacterium tuberculosis.

Panchal RG, Lane D, Boshoff HI, Butler MM, Moir DT, Bowlin TL, Bavari S.

J Antibiot (Tokyo). 2013 Jan;66(1):47-9. doi: 10.1038/ja.2012.93. Epub 2012 Nov 14. No abstract available.

PMID:
23149517
15.

New classes of antibiotics.

Moir DT, Opperman TJ, Butler MM, Bowlin TL.

Curr Opin Pharmacol. 2012 Oct;12(5):535-44. doi: 10.1016/j.coph.2012.07.004. Epub 2012 Jul 26. Review.

PMID:
22841284
16.

Development and application of a cellular, gain-of-signal, bioluminescent reporter screen for inhibitors of type II secretion in Pseudomonas aeruginosa and Burkholderia pseudomallei.

Moir DT, Di M, Wong E, Moore RA, Schweizer HP, Woods DE, Bowlin TL.

J Biomol Screen. 2011 Aug;16(7):694-705. doi: 10.1177/1087057111408605. Epub 2011 May 20.

17.

Identification of a small-molecule entry inhibitor for filoviruses.

Basu A, Li B, Mills DM, Panchal RG, Cardinale SC, Butler MM, Peet NP, Majgier-Baranowska H, Williams JD, Patel I, Moir DT, Bavari S, Ray R, Farzan MR, Rong L, Bowlin TL.

J Virol. 2011 Apr;85(7):3106-19. doi: 10.1128/JVI.01456-10. Epub 2011 Jan 26.

18.

Small molecule inhibitors as countermeasures for botulinum neurotoxin intoxication.

Li B, Peet NP, Butler MM, Burnett JC, Moir DT, Bowlin TL.

Molecules. 2010 Dec 30;16(1):202-20. doi: 10.3390/molecules16010202. Review.

19.

Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates.

Butler MM, Williams JD, Peet NP, Moir DT, Panchal RG, Bavari S, Shinabarger DL, Bowlin TL.

Antimicrob Agents Chemother. 2010 Sep;54(9):3974-7. doi: 10.1128/AAC.00484-10. Epub 2010 Jul 12.

20.

Efflux-mediated bis-indole resistance in Staphylococcus aureus reveals differential substrate specificities for MepA and MepR.

Opperman TJ, Williams JD, Houseweart C, Panchal RG, Bavari S, Peet NP, Moir DT, Bowlin TL.

Bioorg Med Chem. 2010 Mar 15;18(6):2123-2130. doi: 10.1016/j.bmc.2010.02.005. Epub 2010 Feb 10.

PMID:
20188576
21.

Discovery and characterization of inhibitors of Pseudomonas aeruginosa type III secretion.

Aiello D, Williams JD, Majgier-Baranowska H, Patel I, Peet NP, Huang J, Lory S, Bowlin TL, Moir DT.

Antimicrob Agents Chemother. 2010 May;54(5):1988-99. doi: 10.1128/AAC.01598-09. Epub 2010 Feb 22.

22.

Synthesis and biological evaluation of botulinum neurotoxin a protease inhibitors.

Li B, Pai R, Cardinale SC, Butler MM, Peet NP, Moir DT, Bavari S, Bowlin TL.

J Med Chem. 2010 Mar 11;53(5):2264-76. doi: 10.1021/jm901852f.

23.

Barcoding bacterial cells: A SERS based methodology for pathogen identification.

Patel IS, Premasiri WR, Moir DT, Ziegler LD.

J Raman Spectrosc. 2008 Nov;39(11):1660-1672.

24.

Aryl rhodanines specifically inhibit staphylococcal and enterococcal biofilm formation.

Opperman TJ, Kwasny SM, Williams JD, Khan AR, Peet NP, Moir DT, Bowlin TL.

Antimicrob Agents Chemother. 2009 Oct;53(10):4357-67. doi: 10.1128/AAC.00077-09. Epub 2009 Aug 3.

25.

Novel broad-spectrum bis-(imidazolinylindole) derivatives with potent antibacterial activities against antibiotic-resistant strains.

Panchal RG, Ulrich RL, Lane D, Butler MM, Houseweart C, Opperman T, Williams JD, Peet NP, Moir DT, Nguyen T, Gussio R, Bowlin T, Bavari S.

Antimicrob Agents Chemother. 2009 Oct;53(10):4283-91. doi: 10.1128/AAC.01709-08. Epub 2009 Jul 27.

26.

Discovery, characterization and comparison of inhibitors of Bacillus anthracis and Staphylococcus aureus replicative DNA helicases.

Aiello D, Barnes MH, Biswas EE, Biswas SB, Gu S, Williams JD, Bowlin TL, Moir DT.

Bioorg Med Chem. 2009 Jul 1;17(13):4466-76. doi: 10.1016/j.bmc.2009.05.014. Epub 2009 May 12.

27.

Cellular reporter screens for inhibitors of Burkholderia pseudomallei targets in Pseudomonas aeruginosa.

Moir DT, Di M, Moore RA, Schweizer HP, Woods DE.

Trans R Soc Trop Med Hyg. 2008 Dec;102 Suppl 1:S152-62. doi: 10.1016/S0035-9203(08)70033-6.

28.

An essential DnaB helicase of Bacillus anthracis: identification, characterization, and mechanism of action.

Biswas EE, Barnes MH, Moir DT, Biswas SB.

J Bacteriol. 2009 Jan;191(1):249-60. doi: 10.1128/JB.01259-08. Epub 2008 Oct 17.

29.

A high-throughput, homogeneous, bioluminescent assay for Pseudomonas aeruginosa gyrase inhibitors and other DNA-damaging agents.

Moir DT, Ming Di, Opperman T, Schweizer HP, Bowlin TL.

J Biomol Screen. 2007 Sep;12(6):855-64. Epub 2007 Jul 20.

30.

Characterization of the surface enhanced raman scattering (SERS) of bacteria.

Premasiri WR, Moir DT, Klempner MS, Krieger N, Jones G 2nd, Ziegler LD.

J Phys Chem B. 2005 Jan 13;109(1):312-20.

PMID:
16851017
31.

Identification of inhibitors of bacterial enoyl-acyl carrier protein reductase.

Moir DT.

Curr Drug Targets Infect Disord. 2005 Sep;5(3):297-305. Review.

PMID:
16181147
32.

Identification and characterization of inhibitors of bacterial enoyl-acyl carrier protein reductase.

Ling LL, Xian J, Ali S, Geng B, Fan J, Mills DM, Arvanites AC, Orgueira H, Ashwell MA, Carmel G, Xiang Y, Moir DT.

Antimicrob Agents Chemother. 2004 May;48(5):1541-7.

33.

Microbial pathogen genomes - new strategies for identifying therapeutic and vaccine targets.

Opperman T, Ling LL, Moir DT.

Expert Opin Ther Targets. 2003 Aug;7(4):469-73.

PMID:
12885266
34.

Helicobacter pylori physiology predicted from genomic comparison of two strains.

Doig P, de Jonge BL, Alm RA, Brown ED, Uria-Nickelsen M, Noonan B, Mills SD, Tummino P, Carmel G, Guild BC, Moir DT, Vovis GF, Trust TJ.

Microbiol Mol Biol Rev. 1999 Sep;63(3):675-707. Review.

35.

Genomics and antimicrobial drug discovery.

Moir DT, Shaw KJ, Hare RS, Vovis GF.

Antimicrob Agents Chemother. 1999 Mar;43(3):439-46. Review. No abstract available.

36.

Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori.

Alm RA, Ling LS, Moir DT, King BL, Brown ED, Doig PC, Smith DR, Noonan B, Guild BC, deJonge BL, Carmel G, Tummino PJ, Caruso A, Uria-Nickelsen M, Mills DM, Ives C, Gibson R, Merberg D, Mills SD, Jiang Q, Taylor DE, Vovis GF, Trust TJ.

Nature. 1999 Jan 14;397(6715):176-80. Erratum in: Nature 1999 Feb 25;397(6721):719.

PMID:
9923682
37.

Genetic polymorphism of CYP2D6 and lung cancer risk.

Shaw GL, Falk RT, Frame JN, Weiffenbach B, Nesbitt JC, Pass HI, Caporaso NE, Moir DT, Tucker MA.

Cancer Epidemiol Biomarkers Prev. 1998 Mar;7(3):215-9.

38.

Frequency of the variant allele CYP2D6(C) among North American Caucasian lung cancer patients and controls.

Shaw GL, Weiffenbach B, Falk RT, Frame JN, Issaq HJ, Moir DT, Caporaso N.

Lung Cancer. 1997 May;17(1):61-8.

PMID:
9194027
39.

Characterization of a flow-sorted human chromosome 10 cosmid library by FISH.

Ma NS, Zheng C, Benchekroun Y, Deaven LL, Longmire JL, Moir DT, Mao J.

Cytogenet Cell Genet. 1996;74(4):266-71.

PMID:
8976382
40.

Amplification of the copy number of YACs.

Ling LL, Smith DR, Moir DT.

Methods Mol Biol. 1996;54:231-7. No abstract available.

PMID:
8597794
41.

Identification of a YAC spanning the translocation breakpoints in uterine leiomyomata, pulmonary chondroid hamartoma, and lipoma: physical mapping of the 12q14-q15 breakpoint region in uterine leiomyomata.

Fejzo MS, Yoon SJ, Montgomery KT, Rein MS, Weremowicz S, Krauter KS, Dorman TE, Fletcher JA, Mao JI, Moir DT, et al.

Genomics. 1995 Mar 20;26(2):265-71.

PMID:
7601452
42.

A YAC contig spanning a cluster of human type III receptor protein tyrosine kinase genes (PDGFRA-KIT-KDR) in chromosome segment 4q12.

Spritz RA, Strunk KM, Lee ST, Lu-Kuo JM, Ward DC, Le Paslier D, Altherr MR, Dorman TE, Moir DT.

Genomics. 1994 Jul 15;22(2):431-6.

PMID:
7528718
43.
44.

Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype.

Saxena R, Shaw GL, Relling MV, Frame JN, Moir DT, Evans WE, Caporaso N, Weiffenbach B.

Hum Mol Genet. 1994 Jun;3(6):923-6.

PMID:
7951238
45.

Reduced occurrence of chimeric YACs in recombination-deficient hosts.

Ling LL, Ma NS, Smith DR, Miller DD, Moir DT.

Nucleic Acids Res. 1993 Dec 25;21(25):6045-6. No abstract available.

46.

Rapid identification of overlapping YACs in the MEN2 region of human chromosome 10 by hybridization with Alu element-mediated PCR products.

Moir DT, Dorman TE, Xue F, Ma NS, Stanton VP Jr, Housman D, Bowden DW, Noll WW, Mao J.

Gene. 1993 Dec 22;136(1-2):177-83.

PMID:
7904972
47.

A human genome YAC library in a selectable high-copy-number vector.

Moir DT, Dorman TE, Smyth AP, Smith DR.

Gene. 1993 Mar 30;125(2):229-32.

PMID:
8462878
48.
49.

The (4;11)(q21;q23) chromosome translocations in acute leukemias involve the VDJ recombinase.

Gu Y, Cimino G, Alder H, Nakamura T, Prasad R, Canaani O, Moir DT, Jones C, Nowell PC, Croce CM, et al.

Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10464-8.

50.

Copy number amplification of yeast artificial chromosomes.

Smith DR, Smyth AP, Moir DT.

Methods Enzymol. 1992;216:603-14. No abstract available.

PMID:
1336106

Supplemental Content

Support Center